O46.019 Antepartum hemorrhage with afibrinogenemia, unspecified trimester

Name of the Condition

• Antepartum Hemorrhage with Afibrinogenemia, Unspecified Trimester

Summary

Antepartum hemorrhage refers to bleeding from the genital tract during pregnancy, typically after 20 weeks of gestation. When associated with afibrinogenemia, the bleeding is exacerbated by a severe deficiency of fibrinogen, a critical protein for blood clotting. This condition can complicate management and increase risks to both the mother and fetus due to impaired clot formation.

Causes

Afibrinogenemia in antepartum hemorrhage may result from congenital deficiencies (e.g., inherited fibrinogen disorders) or acquired conditions such as severe liver disease, disseminated intravascular coagulation (DIC), or massive blood loss that depletes fibrinogen stores. Pregnancy-related complications like placental abruption or previa can also trigger or worsen this coagulation defect.

Risk Factors

• Congenital fibrinogen deficiency
• Severe liver dysfunction
• Previous history of bleeding disorders
• Placental abruption or previa
• Multiple pregnancies
• Use of anticoagulant medications

Symptoms

• Vaginal bleeding (ranging from spotting to heavy flow)
• Excessive bruising or prolonged bleeding from minor injuries
• Fatigue or weakness (due to blood loss)
• Signs of coagulation issues, such as petechiae or uncontrolled bleeding

Diagnosis

Diagnosis involves assessing the bleeding pattern and evaluating coagulation status. Laboratory tests, including fibrinogen levels and coagulation profiles, help confirm afibrinogenemia. Imaging studies may be used to identify underlying causes like placental abnormalities. Clinical correlation with symptoms and history is essential for accurate diagnosis.

Treatment Options

Treatment focuses on controlling bleeding and correcting fibrinogen deficiency. Interventions may include blood transfusions, fibrinogen replacement therapy, and management of the underlying cause (e.g., treating placental abruption). Close monitoring of maternal and fetal status is critical, with delivery considered if maternal or fetal health is compromised.

Prognosis and Follow-Up

Prognosis depends on the severity of bleeding, timely intervention, and underlying causes. Complications like maternal hemorrhage or fetal distress may occur. Follow-up includes monitoring coagulation parameters, assessing for recurrence, and addressing any residual coagulation defects. Long-term management may involve genetic counseling for congenital cases.

Complications

• Severe maternal hemorrhage
• Fetal distress or loss
• Disseminated intravascular coagulation (DIC)
• Postpartum hemorrhage
• Anemia or shock from blood loss

Lifestyle & Prevention

• Avoid activities with high injury risk during pregnancy.
• Manage underlying conditions (e.g., liver disease) with medical guidance.
• Attend regular prenatal care to monitor coagulation status.
• Inform healthcare providers of any bleeding history or clotting disorders.

When to Seek Professional Help

Seek immediate medical attention for:

• Heavy or persistent vaginal bleeding.
• Signs of shock (e.g., dizziness, rapid heartbeat).
• Uncontrolled bleeding from minor injuries.
• Fetal movement changes or reduced activity.

Tips for Medical Coders

Document the trimester (if specified) and confirm afibrinogenemia as the coagulation defect. Ensure clinical correlation with bleeding events and laboratory results. Use this code when the condition is unspecified by trimester and afibrinogenemia is the primary coagulation issue.